AbbVie Inc. (ABBV)
Pre-market:
| Previous close | 151.96 |
| Open | 151.63 |
| Bid | 150.48 x 900 |
| Ask | 0.00 x 900 |
| Day's range | 150.39 - 153.07 |
| 52-week range | 105.56 - 175.91 |
| Volume | |
| Avg. volume | 7,381,880 |
| Market cap | 266.074B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 21.60 |
| EPS (TTM) | 6.97 |
| Earnings date | 28 Jul 2022 - 01 Aug 2022 |
| Forward dividend & yield | 5.64 (3.71%) |
| Ex-dividend date | 14 Apr 2022 |
| 1y target est | 164.45 |
- Zacks
Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
- Motley Fool
3 Healthcare Stocks You Can Buy and Hold for the Next Decade
You know that you can count on them for leadership in their market and earnings growth. Here, I'll focus on three companies that stand out for their strong market positions: a biotech company and a medical device company that each dominate their fields, and a pharmaceutical player on the way to winning in market share. Vertex Pharmaceuticals (NASDAQ: VRTX) is the worldwide leader in cystic fibrosis (CF) treatment.
- Zacks
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
